Omnix Medical develope and commercialize highly effective antibiotic agents against resistant pathogenic bacterial strains.
Omnix Medical is dedicated to the development and commercialization of highly effective antibiotic agents against resistant pathogenic bacterial strains. Omnix is addressing an enormous and rapidly growing threat to public health, represented by millions worldwide, who suffer from infections associated with resistant bacteria. Omnix’s technology will tilt the odds in the battle against resistant bacteria and improve the lives of many people worldwide.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Aug 31, 2021 | Grant | — | 1 | National Institutes of Health | — | Detail |
Jan 25, 2021 | Grant | €10.80M | 1 | European Innovation Council | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
National Institutes of Health | Yes | Grant |
European Innovation Council | Yes | Grant |